dc.description.sponsorship | Dr Salloum is supported by the National Heart, Lung, and Blood
Institute of the National Institutes of Health under Award Numbers
R35HL155651 and R44HL164314, and the American Heart Association
Strategically Focused Research Network Award Number
23SFRNPCS1063855. Dr Tocchetti is supported by grants from the
Italian Ministry of Health (PNRR-MAD-2022-12376632 and RF-2016-
02362988). Dr Ameri is supported by the European Union - Next
Generation EU - NRRP M6C2 - Investment 2.1 “Enhancement and
strengthening of biomedical research in the NHS” (Italian Ministry of
Health PNRR-MAD-2022-12376632). Dr Ardehali is supported by the
National Heart, Lung, and Blood Institute of the National Institutes of
Health under Award Numbers HL127646, HL140973, HL138982, and
HL140927. Dr Asnani is supported by R01HL163172, R01HL166541,
R01HL157530, and K08HL145019 from the National Institutes of
Health/National Heart, Lung, and Blood Institute and by a sponsored
research agreement with Genentech. Dr de Boer is supported by the
Netherlands Heart Foundation (grants 2017-21, 2017-11, 2018-30, and
2020B005), the Leducq Foundation (Cure-PLaN), and the European
Research Council (ERC CoG 818715). Dr Fernández-Velasco is
supported by the Carlos III Health Institute (ISCIII) (PI20-01482
and PMP22/00098). Dr Fradley is funded by Medtronic and AstraZeneca. Dr Fuster is supported by grant RYC-2016-20026 from the
Spanish Ministerio de Ciencia e Innovación (MICIN/AEI/10.13039/
501100011033 and “ESF Investing in your future”) and the European
Research Area Network on Cardiovascular Diseases CHEMICAL (grant
AC19/00133, funded by ISCIII and co-funded by the European Union,
ERDF, “A way to make Europe”). Drs Galán-Arriola, García-Lunar,
Ibáñez, and Martin and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) are supported by the ISCIII, the Ministry of Science and Innovation, and the Pro CNIC Foundation, and is a Severo
Ochoa Center of Excellence (grant CEX2020-001041-S funded by
MICIN/AEI/10.13039/501100011033). Dr Ibáñez is supported by a European Research Council grant (ERC-CoG 819775). The RESILIENCE
project has received funding from the European Union’s Horizon 2020
research and innovation program under grant agreement No 945118.
Dr Kitsis is supported by the national Heart, Lung, and Blood Institute
of the National Institutes of Health under Award Numbers
R01HL159062, R01HL157319, R01HL164772, and DOD PR191593. Dr
Martin is supported by MCIN-ISCIII-Fondo de Investigación Sanitaria
(PI22/01759; PMPTA22/00090-BIOCARDIOTOX) and the Comunidad
de Madrid (P2022/BMD-7209-INTEGRAMUNE-CM). Dr Mauro is supported by T32HL149645. Dr Mazo Vega is supported by European
Union’s H2020 Program under grant agreement No 874827 (BRAVd)
and the Ministerio de Ciencia e Innovación CARDIOPRINT (PLEC2021-
008127). Dr Neilan is supported by a gift from A. Curt Greer and Pamela
Kohlberg and from Christina and Paul Kazilionis, the Michael and
Kathryn Park Endowed Chair in Cardiology, and a Hassenfeld Scholar
Award, and is supported by additional grant funding from the National Institutes of Health/National Heart, Lung, and Blood Institute
under Award Numbers R01HL137562 and K24HL150238. Dr Rassaf is
supported by the German Research Foundation Lower Saxony (DFG
RA969/12-1), Ministry of Science and Culture REBIRTH I/II (ZN3440),
and Stiftung Gerdes. Dr Ricke-Hoch is supported by the Lower Saxony
Ministry of Science and Culture REBIRTH I/II (ZN3440) and Stiftung
Gerdes. Dr van der Meer is supported by a grant from the European
Research Council (ERC CoG 101045236, DISSECT-HF). Dr Thavendiranathan is supported by a Tier II Canada Research Chair in Cardiooncology (950-232646). Dr Ky is supported by National Institutes of
Health grants R01 HL148272, R01 HL152707, R34 HL146927, R21
HL152148, R21HL157886, and K24 HL167127 and American Heart Association Strategically Focused Research Network Awards 849569 and
869105. Dr Sepulveda is supported by ISCIII (PMPTA2022/00011). Drs Ghigo, Lyon, Ibáñez, Hirsch, Ricke-Hoch, and Rassaf are supported by
the Leducq Foundation Transatlantic Networks of Excellence
(19CVD02). Dr Salloum has received consulting fees from Ring Therapeutics and funding from Novartis Pharmaceuticals, not related to
this work; and served on the advisory board for NovoMedix, LLC, in
cardio-oncology but not directly related to this work. Dr Tocchetti has
received honoraria or consultation fees from VivaLyfe, Univers Formazione, Solaris, Summeet, AstraZeneca, and Myocardial Solutions;
has received funding from Amgen and MSD, outside the submitted
work; and is listed as an inventor of 2 patents related to heart failure.
Dr Ameri has received speaker and/or advisor fees from AstraZeneca,
Boehringer Ingelheim, Bayer, Novartis, Daiichi Sankyo, Janssen, and
MSD, all outside the submitted work. Dr Asnani has served as a
consultant or advisory board member for Sanofi, AstraZeneca, Cytokinetics, and OncLive; served as the principal investigator of a sponsored research agreement with Genentech; and received honoraria
from UpToDate. Dr de Boer has received research grants and/or fees
from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and
served as a speaker for Abbott, AstraZeneca, Bayer, Bristol Myers
Squibb, Novartis, and Roche. Dr Fradley has served as a consultant for
AbbVie, AstraZeneca, Johnson and Johnson, Pfizer/Myovant, and Zoll.
Drs Ghigo and Hirsch are co-founders and shareholders of Kither
Biotech, a pharmaceutical company focused on the development of
PI3K inhibitors for airway diseases not in conflict with the content of
this paper. Dr Kitsis is a founder of ASPIDA Therapeutics Inc. Dr Lyon
has received speaker, advisory board, or consulting fees and/or
research grants from Pfizer, Novartis, Servier, AstraZeneca, Bristol
Myers Squibb, GSK, Amgen, Takeda, Roche, Janssen-Cilag Ltd,
Astellas Pharma, Clinigen Group, Eli Lilly, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health, and Heartfelt Technologies Ltd. Dr Neilan has
served as a consultant for and received fees from Bristol Myers Squibb,
Genentech, CRC Oncology, Roche, Sanofi, and Parexel Imaging Pharmaceuticals; and received grant funding from AstraZeneca and Bristol
Myers Squibb related to immune therapies. Dr Rassaf has received
honoraria, lecture fees, and grant support from Edwards Lifesciences,
AstraZeneca, Bayer, Novartis, Berlin Chemie, Daiichi Sankyo, Boehringer Ingelheim, Novo Nordisk, Cardiac Dimensions, and Pfizer, all
unrelated to this work. Dr Thavendiranathan’s institution has
received speaker honoraria or consultation fees from Amgen, Novartis, Boehringer Ingelheim, and Takeda. Dr van der Meer has received
consulting fees and/or grants from Novartis, Pharmacosmos, Vifor
Pharma, AstraZeneca, Pfizer, Pharma Nord, BridgeBio, Novo Nordisk,
Boehringer Ingelheim, and Ionis. Dr Ky has received honoraria or
grants from Pfizer; and honoraria from Roche, Bristol Myers Squibb,
and AstraZeneca. Dr López-Fernández has received speaker fees from
Philips, Janssen, Daichi Sankyo, Myocardial Solutions, AstraZeneca,
Beigene, and Bayer, not related to the current work. All other authors
have reported that they have no relationships relevant to the contents
of this paper to disclose. | es_ES |